Next Generation of CO2 Incubators for Demanding Cell Culture Applications
Cell culture scientists working with sensitive cultures such as stem and primary cells, can turn to a new CO2 incubator that combines the latest technologies for optimal cell growth and contamination control designed to create uniform growth conditions with consistency and reliability.
The Thermo Scientific Heracell VIOS incubator series is ideal for academic research and pharmaceutical applications, allowing scientists to maximize their productivity with excellent reproducibility, reliability and efficiency.
“Reproducibility and contamination prevention are critical when it comes to sensitive cultures to ensure the integrity of your research,” said Doug Wernerspach, Global Business Director, Thermo Fisher Scientific. “Our new Heracell VIOS series leverage our long history of CO2 technology leadership with innovations, including our new THRIVE active airflow and proven decontamination that are critical for today’s demanding cell culture applications.”
Incorporating the breakthrough THRIVE active airflow technology, the Heracell VIOS delivers a homogeneous culturing environment with fast recovery for unwanted variation. Designed to protect valuable cultures from contamination, the Heracell VIOS is equipped with
• ISO class 5 HEPA filters to protect against airborne microbes and particulates
• Steri-Run, a fully automatic on-demand overnight 180 °C sterilisation cycle assures uniform 6-log high-temperature sterilisation on all surfaces
• Condensation-free chamber with covered, protected humidity reservoir
• 100% pure copper interiors to provide lasting sustainability and easy maintenance.
For operation simplicity, the intelligent iCAN touchscreen interface provides complete data visibility to monitor all incubator interaction, featuring on-screen menu prompts, error and usage monitoring, downloadable data logging with a standard USB, performance trend graphing and multiple language selection, including English, Spanish, German, French, Italian, Japanese and Mandarin.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance